A New Routine
Everyone has been adjusting to COVID-19 life for a year and, during that time, Metabolon has found its new routine with a productive hybrid model. Our lab staff continues to impress with the level of care to the highest quality standards while protecting fellow team members against COVID-19. Since day one, we have taken extra precautions for the safety and well-being of our team. Once we were able, we prioritized getting our onsite lab staff access to vaccines as essential personnel moving science forward.
Recognized for our cutting-edge approach to metabolomics, Metabolon has been a valued resource for COVID-19 researchers worldwide. Our actionable metabolomic insights have fueled pivotal and high-profile studies like the National Institute of Allergy and Infectious Diseases (NIAID) IMPACC study research to improve understanding of high-risk patients. These and other metabolomics projects are helping get closer to the phenotype and pressing forward on COVID-19 answers. Institute for Systems Biology research to improve understanding of high-risk patients. These and other metabolomics projects are helping get closer to the phenotype and pressing forward on COVID-19 answers.
Supporting Decentralized Metabolomics Testing Location Needs
The scientific community has learned a lot this year. We know that your research has been faced with unprecedented circumstances due to the COVID pandemic, limiting the ability of patients to access the lab for the collection of blood plasma and serum. This dynamic has slowed or prevented many research programs globally. While there are now vaccine options, greater caution will surround us for some time. To continue to support your metabolomic research needs, including facilitating remote clinical trials, we have invested in alternative sampling methods to meet decentralized testing location needs.
We are eager to join you in the fight to stop this global health crisis. Please contact your Metabolon Sales Representative or email us at firstname.lastname@example.org to discuss your specific program needs.
Dried blood spot (DBS) cards
The ability to sample and ship small volumes of blood on a DBS card represents an alternative to in-clinic visits, allowing monitoring of vulnerable patients and testing of remote populations without escalating sampling costs. DBS cards allow sampling of small volumes with less invasive devices, providing an ideal solution for frequent collections such as for human longitudinal studies and animal pharmacokinetics and pharmacodynamic studies that require frequent collections – sometimes daily or even hourly.
This in-home collection device for metabolomics study of fecal samples delivers needed flexibility for microbiome studies. The proprietary stabilization chemistry in the OMNImet·GUT device provides ambient-temperature stability that does not require immediate freezing and cumbersome and expensive cold-chain logistics. The design maintains the integrity of the sample for metabolomics analysis for multiple days at ambient temperature. The increased flexibility, ease of use, and lower shipping costs provided by OMNImet·GUT device can offer significant advantages to clinical trial recruitment and execution.
What you need to know about how we are adjusting our business in response to the coronavirus (COVID19) to continue to meet the needs of our clients. If your question is not addressed here, please contact us at email@example.com for more information. (Updated 4/27/2021)
Yes. The current CDC Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 states that routine diagnostic testing of specimens can be handled in a biosafety level 2 (BSL-2) laboratory using Standard Precautions. Metabolon is BSL-2 certified for all biological sample types, including serum, plasma, urine, and feces. Please refer to General Question 3 below for guidance or contact us for more information.
The COVID-19 situation has required us to adapt to the new normal. Early on in the pandemic we made updates to our business operations to ensure you continue to receive the highest quality service without disruption while keeping our employees safe. We will continue to keep our clients and stakeholders apprised of operational changes as the situation evolves.
- We have been closely monitoring guidance from the World Health Organization and local authorities throughout our business footprint. The recommendations have led us to activate our robust Business Continuity Plan with specific steps to account for COVID-19. We are focused on both protecting the health and welfare of our employees and implementing updated business procedures to ensure we continue providing on-time delivery of your projects.
- We have asked our desk-based employees to work from home as a precaution, supporting guidance from the World Health Organization and Centers for Disease Control that encourage social distancing.
- For our lab-based employees, we implemented hybrid schedules to reduce the number of people in one place at one time and continuing to maintain stringent handwashing and cleaning practices. These measures will both ensure the safety of our staff and the on-time delivery of your project.
- Our lab-based staff are classified at front line workers due to the nature of the research we are involved in and have had access to the vaccine.
- Metabolon is and has always been committed to the health and safety of our employees and our community. As such, all samples are treated in accordance with strict lab safety protocols including the use of proper personal protective equipment (PPE), proper biohazardous waste handling practices, and extensive environmental controls including bio safety cabinets.
- Metabolon is capable of handling BSL2 biofluids and solid samples for research.
- Metabolon can accept other, non-fecal, biosolid types contaminated with BSL2/Class 2 agents as our protocols for these steps maintains safety requirements with either methanol soak or other similar processes. For accepting cell pellets, we require customers to provide an accurate cell count for normalization purposes.
We are continuing to receive samples per normal operations. Dedicated staff will be onsite at our RTP site each day to meet global couriers such as World Courier, UPS and FedEx.
- Please send your samples by your previously agreed upon delivery date or sooner, if possible.
- We are continuing to receive samples per normal business operations and will have someone onsite each day to meet our global couriers such as World Courier, UPS and FedEx.
- Once you ship your samples, please provide your client success manager and SampleManager@metabolon.com a tracking number so we can be sure to know when to expect the delivery.
- While we have made some adjustments to our business practices in light of COVID-19, we continue to operate at full capacity and do not anticipate any major delays in our ability to deliver your project on time. If we encounter any challenges, we will notify you immediately.
- Please do not hesitate to contact your sales representative or client success manager if you have questions about your project timetable.
- While Metabolon has implemented business continuity practices that allow staff to work remotely or in shifts to enable social distancing, our Client Success project managers and Study Directors continue to be available to you during regular office hours.
- As per standard practice, please continue to reach out to your regular Client Success and Study Director contacts once you have shipped samples.
- While Metabolon has implemented business continuity practices that allow for staff to work remotely or in shifts to enable social distancing, we continue to operate at full capacity.
- We do not anticipate any major delays in project delivery, but if we encounter any challenges, we will notify you immediately.
We will return samples as per our current agreements with each client provided no employees at our RTP headquarters have tested positive for COVID-19 or exhibited symptoms requiring COVID-19 testing.
If you determine that your study submitted samples from any patient exposed to COVID-19, please notify us immediately. We will notify the North Carolina Department of Health and Human Services and take appropriate action based on their guidance.
Understanding the pathophysiology and immune response of infectious diseases is vital for discovering effective treatments. These case studies support several problem-oriented metabolomics applications to SARS-CoV-2 by identifying metabolomic changes during infection and predicting disease severity and need for effective intervention and efficacy.
When dealing with a pandemic like COVID-19, vaccine development and discovery of therapeutics are essential to improving outcomes. These case studies address the need for actionable insights for vaccine development that metabolomics provides through a comprehensive view driving operational and quality improvements and antibody production.
Understanding the effects of age, gender and comorbidities on susceptibility to COVID-19, response to treatment and outcomes like mortality are vital for improved outcomes. These case studies highlight how metabolomics guides effective intervention and efficacy.
Comprehensive metabolomic profiling can simultaneously inform on several biological processes relevant to infection, such as inflammatory and redox markers, energetics, microbiome contribution and xenobiotic impact. These insights can lead to predictive response signatures and therapy strategies. The following case studies demonstrate how metabolomics enhances understanding of viral activity, helps to predict viral treatment and supports informed decisions on vaccine development.
Enlighten your research,
accelerate your discovery.
617 Davis Drive, Suite 100
Morrisville, NC 27560
P.O. Box 110407
Research Triangle Park, NC 27709